Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha

BMC Endocrine Disorders

Research

Yisi Liu¹  Shan Ren¹  Sujun Zheng¹  Yanhong Zheng¹  Zhongjie Hu¹  Lina Ma¹  Xinyue Chen¹  Xiao Lin¹  Junfeng Lu¹  Bin Xu²  Zhenhuan Cao³ 

[1] First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, No.8, Xi Tou Tiao, Youanmen Wai, 100069, Beijing, Fengtai District, China;Second Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China;Third Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China;

关键词: Thyroid diseases;    Chronic hepatitis B;    Interferon alpha;    Side effect;    Functional cure;   

DOI  :  10.1186/s12902-023-01371-w

 received in 2023-02-20, accepted in 2023-05-12,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThyroid disorders (TD) is a common complication of pegylated-interferon alpha (Peg-IFNα) therapy. Few studies have investigated the relationship between TD and the efficacy of interferon therapy for chronic hepatitis B (CHB). Therefore, we analyzed the clinical characteristics of TD in patients with CHB treated with Peg-IFNα, and evaluated the correlation between TD and Peg-IFNα treatment efficacy.MethodsIn this retrospective study, the clinical data of 146 patients with CHB receiving Peg-IFNα therapy were collected and analyzed.ResultsDuring the course of Peg-IFNα therapy, positive conversion of thyroid autoantibodies and TD occurred in 7.3% (85/1158) and 8.8% (105/1187) patients, respectively, and was diagnosed more often in women. The most common thyroid disorder was hyperthyroidism (53.3%), followed by subclinical hypothyroidism (34.3%). We found that thyroid function returned to normal in 78.7% of patients with CHB, and thyroid antibody levels returned to the negative range in approximately 50% of patients after interferon treatment cessation. Only 25% of patients with clinical TD required treatment. Compared with patients with hypothyroidism/subclinical hypothyroidism, patients with hyperthyroidism/subclinical hyperthyroidism showed greater reduction and seroclearance of hepatitis B surface antigen (HBsAg) levels.ConclusionsTD are not an absolute contraindication for interferon therapy; however, patients should be monitored closely during interferon therapy. In pursuit of functional cure, a balance between efficacy and safety must be achieved.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 8

41116_2023_36_Article_IEq237.gif

41116_2023_36_Article_IEq224.gif